GVHD Clinical Trial
Official title:
Phase I Trial of Brentuximab Vedotin for Refractory Chronic Graft-vs.-Host Disease (GVHD)
NCT number | NCT01940796 |
Other study ID # | 13-239 |
Secondary ID | |
Status | Terminated |
Phase | Phase 1 |
First received | |
Last updated | |
Start date | October 2013 |
Est. completion date | December 2016 |
Verified date | July 2018 |
Source | Massachusetts General Hospital |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
This research study is trying to determine the safest dose of Brentuximab Vedotin that can be given to patients with chronic GVHD and see if chronic GVHD improves.
Status | Terminated |
Enrollment | 19 |
Est. completion date | December 2016 |
Est. primary completion date | December 2016 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility |
Inclusion Criteria: - Recipients of allogeneic hematopoietic cell transplantation (HCT) after either myeloablative or reduced intensity conditioning regimens. Any donor source of stem cells is eligible. - Participants must be at least 100 days after HCT. - Patients must have steroid refractory cGVHD, defined as having persistent signs and symptoms of chronic GVHD (section 13.1) despite the use of prednisone at = 0.25 mg/kg/day (or 0.5 mg/kg every other day) for at least 4 weeks in the preceding 12 months (or equivalent dosing of alternate corticosteroids) without complete resolution of signs and symptoms. - Stable dose of corticosteroids for 4 weeks prior to enrollment - No addition or subtraction of other immunosuppressive medications (e.g., calcineurin inhibitors, sirolimus, mycophenolate mofetil) for 4 weeks prior to enrollment. The dose of immunosuppressive medicines may be adjusted based on the therapeutic range of that drug - Serum Cr = 3 gm / dL - Adequate hepatic function (total bilirubin < 2.0 mg/dl, AST < 5x ULN), unless hepatic dysfunction is a manifestation of presumed cGVHD. For patients with abnormal LFTs as the sole manifestation of active cGVHD, documented cGVHD on liver biopsy will be required prior to enrollment. Abnormal LFTs in the context of active cGVHD involving other organ systems may also be permitted if the treating physician documents the abnormal LFTs as being consistent with active hepatic cGVHD, and a liver biopsy will not be mandated in this situation. - Patients must have adequate bone marrow function as defined by ANC = 1000 / µl and platelets = 20,000 / µl without growth factor or transfusional support - Negative pregnancy test for females of child bearing age - Age = 18 - The safety and effectiveness of brentuximab vedotin has not been established in the pediatric population. Clinical trials of brentuximab vedotin included only 9 pediatric patients and this number is not sufficient to determine whether they respond differently than adult patients. - The effects of brentuximab vedotin on the developing human fetus are unknown. For this reason and because chemotherapy agents are known to be teratogenic, women of child-bearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry and for the duration of study participation. Should a woman become pregnant or suspect she is pregnant while participating in this study, she should inform her treating physician immediately. - Ability to understand and the willingness to sign a written informed consent document Exclusion Criteria: - Ongoing prednisone requirement > 1 mg/kg/day (or equivalent) - Exposure to any new immunosuppressive medication in the 4 weeks prior to enrollment. - ECP therapy within 4 weeks prior to enrollment - Active malignant disease relapse - Active, uncontrolled infection - Uncontrolled cardiac angina or symptomatic congestive heart failure (NYHA Class III or IV). - Karnofsky performance status < 30 - Prior use of brentuximab vedotin for GVHD is not allowed. Prior use of brentuximab vedotn for the treatment of malignancy is allowed. - Pregnant women are excluded from this study because brentuximab vedotin is a chemotherapy agent with the potential for teratogenic or abortifacient effects. Because there is an unknown but potential risk of adverse events in nursing infants secondary to treatment of the mother with brentuximab vedotin, breastfeeding should be discontinued if the mother is treated with brentuximab vedotin. |
Country | Name | City | State |
---|---|---|---|
United States | Massachusetts General Hospital | Boston | Massachusetts |
Lead Sponsor | Collaborator |
---|---|
Massachusetts General Hospital | Seattle Genetics, Inc. |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | To define the maximum tolerated dose (MTD) of brentuximab vedotin when given as treatment for refractory chronic GVHD | To define the maximum tolerated dose (MTD) of brentuximab vedotin when given as treatment for refractory chronic GVHD | 2 Years | |
Secondary | To test the overall response rate of Brentuximab Vedotin when given as treatment for refractory chronic GVHD | To test the overall response rate of Brentuximab Vedotin when given as treatment for refractory chronic GVHD | 2 Years | |
Secondary | To identify the toxicities associated with Brentuximab Vedotin when used as therapy for refractory chronic GVHD | To identify the toxicities associated with Brentuximab Vedotin when used as therapy for refractory chronic GVHD | 2 Years | |
Secondary | Overall Survival | Overall survival at 100 days, 180 days, and one year after first infusion | 2 Years | |
Secondary | To assess levels of soluble CD30 and surface CD30 expression on peripheral blood T-cells in participants with chronic GVHD before and after the administration of brentuximab vedotin | To assess levels of soluble CD30 and surface CD30 expression on peripheral blood T-cells in participants with chronic GVHD before and after the administration of brentuximab vedotin | 2 Years | |
Secondary | To assess dose of steroids (mg/kg/day of prednisone equivalent) at 6 and 12 months after starting therapy | To assess dose of steroids (mg/kg/day of prednisone equivalent) at 6 and 12 months after starting therapy | 2 Years |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT02942173 -
CD45RA Depleted T-cell Infusion for Prevention of Infections After TCRab/CD19-depleted Allo-HSCT
|
Phase 2/Phase 3 | |
Completed |
NCT02066051 -
IPL and Meibomian Gland Expression to Treat Ocular Rosacea Ocular GVHD
|
N/A | |
Not yet recruiting |
NCT05544448 -
In Vitro Effect Study of Interleukin-2 Muteins on Regulatory T Cells of Patients With Different Autoimmune, Allo-immune or Inflammatory Diseases
|
N/A | |
Completed |
NCT01295710 -
Study of US-ATG-F to Prevent Chronic Graft Versus Host Disease (GVHD)
|
Phase 3 | |
Not yet recruiting |
NCT06000982 -
Comparison of Different Dose of Post-transplantation Cyclophosphamide as Graft Versus Host Disease Prophylaxis
|
Phase 3 | |
Not yet recruiting |
NCT06075225 -
MAP-guided Preemptive Therapy of aGvHD by Ruxolitinib
|
Phase 2 | |
Active, not recruiting |
NCT03680092 -
Comparing Cyclophosphamide and Abatacept With Standard of Care Treatment Following Stem Cell Transplantation
|
Phase 2 | |
Not yet recruiting |
NCT06083129 -
Phase III Study Comparing GVHD Prophylaxis With ATG-thymoglobulin to ATLG-grafalon in Elderly Patients With Acute Myeloid Leukemia or Myelodysplasic Syndrome and Receiving an Allogeneic Hematopoietic Stem Cell Transplantation With a 10/10 HLA Matched Unrelated Donor
|
Phase 3 | |
Not yet recruiting |
NCT05094765 -
Fecal Microbiota Transplant (FMT) Capsule for Improving the Efficacy of GI-aGVHD
|
Early Phase 1 | |
Active, not recruiting |
NCT05415410 -
Proof-of-concept Trial of Apraglutide in GVHD
|
Phase 2 | |
Completed |
NCT02441075 -
70% Ethanol for Decontamination of CVL Exposed to Calcineurine Inhibitors Version 1.0, 1/9/2014
|
N/A | |
Completed |
NCT02588339 -
Panobinostat (LBH589): Acute Graft Versus Host Disease (aGVHD) Prevention
|
Phase 2 | |
Not yet recruiting |
NCT06334367 -
Prophylaxis of Graft-versus-host Disease With Anti-CD25 Antibody in Patients Underwent HSCT
|
Phase 2 | |
Completed |
NCT03846479 -
Itacitinib for Low Risk GVHD
|
Phase 2 | |
Completed |
NCT02891603 -
A Phase I/II GVHD Prevention Trial Combining Pacritinib With Sirolimus-Based Immune Suppression
|
Phase 1/Phase 2 | |
Completed |
NCT02712762 -
Ocular Surface Disease in Chronic Graft-Versus-Host Disease (GVHD) Patients
|
||
Completed |
NCT03945591 -
High-Dose Post-Transplant Cyclophosphamide and Bortezomib (CyBor) for the Prevention of Graft-versus-Host Disease Following Allogeneic Hematopoietic Stem Cell Transplantation (HSCT)
|
Phase 2 | |
Not yet recruiting |
NCT06411184 -
Safety and Efficacy of Treg Cell in the Treatment of GVHD
|
Phase 1/Phase 2 | |
Terminated |
NCT02338232 -
Study of TelmisartanFor the Prevention of Acute GVHD Post Allogeneic Hematopoietic Stem Cell Transplantation
|
N/A | |
Completed |
NCT02156479 -
Clinical Validation of Lophius Biosciences Kit T-Track® CMV in Allo-HSCT Recipients
|